April 20, 2024
Stocks & Bonds
[EQUITIES] ‘Osstem Implant’s overseas sales rise’
[THE INVESTOR] Osstem Implant will continue growing on the back of brisk sales overseas, said Shinhan Financial Securities on Jan. 18, upgrading its recommendation to a “buy” from a “trading buy” and raising the target price to 68,000 won (US$58.42) from 65,000 won.
It will post record earnings in the fourth quarter last year at 96.1 billion won, up 18.3 percent on-year, and operating profit will rise 7.3 percent to 14.2 billion won, said analyst Bae Gi-dal.
The figures are largely due to the spike in implant exports that rose 45.2 percent on-year, and increase in revenue from overseas branches at 27.7 percent, according to the analyst.
“Its revenue from Chinese operations recovered from the downturn in two previous quarters, increasing 31.8 percent to 16.9 billion won, and both implant exports and sales through overseas branches will post double-digit growth rate,” said Bae.
By Hwang You-mee (glamazon@heraldcorp.com)
It will post record earnings in the fourth quarter last year at 96.1 billion won, up 18.3 percent on-year, and operating profit will rise 7.3 percent to 14.2 billion won, said analyst Bae Gi-dal.
The figures are largely due to the spike in implant exports that rose 45.2 percent on-year, and increase in revenue from overseas branches at 27.7 percent, according to the analyst.
“Its revenue from Chinese operations recovered from the downturn in two previous quarters, increasing 31.8 percent to 16.9 billion won, and both implant exports and sales through overseas branches will post double-digit growth rate,” said Bae.
By Hwang You-mee (glamazon@heraldcorp.com)
